C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer models

C2i Genomics (EFL Life Sciences, ‘20), a cancer intelligence company, announced an extension of a collaboration with AstraZeneca to evaluate whole-genome minimal residual disease (MRD) testing across solid cancers.

“This collaboration has generated promising results by providing ultra-sensitive and accurate cancer detection and monitoring across multiple solid cancers,” said Asaf Zviran, CEO and co-founder of C2i Genomics.